Business Wire

DNBC-FINANCIAL-GROUP

13.4.2022 18:35:14 CEST | Business Wire | Press release

Share
5 Reasons to Make International Business Payments via Business Account - DNBC Financial Group

To make a big achievement in today's global economy and win sales against overseas competition, businesses must provide their clients with appealing sales conditions accompanied by proper international business payments mechanisms. The most common way to pay international business invoices is via bank wire transfer or credit unions, yet the currency exchange rate is high.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220413005543/en/

Another option is believed to be one of the best international payment solutions for business is via online payment providers. DNBC now will show you 5 reasons to make international business payments via business account to avoid losing potential customers to competition by failing to consider other payment choices.

1. Being Transparent

Businessmen are concerned they would be charged high fees if they want to make international business payments. Making cross-border payments may be complicated and costly due to hidden fees and confusing exchange rate calculations. Make sure you always know the exchange rates and costs associated with money transfer services prior to making a transaction.

2. Transferring around the world in multiple currencies

Cash is still preferred when making purchases, but not everyone is willing to accept it, especially when making international business payments. Paying mortgages and other invoices in a foreign nation is a tremendous demand for any businessman.

At DNBC Financial Group , we enable SWIFT and SEPA transfers to 170 countries and territories worldwide, providing our clients with a range of transfer alternatives at the lowest possible rate and with the least amount of wait time.

3. Organizing Your Business Records

Having a business checking account to make international business payments is a great idea for businessmen to manage their firm. The account may store both receipts and expenditure checks, which helps you keep track of costs, check up on spending, avoid overspending and calculate profit margin in an easy way.

With DNBCnet Mobile App , you may check the balance on your payment card at any time and from any location through DNBCnet, SMS Banking, or any ATM. Moreover, we also support exporting e-statements of your transactions over the course of a month or many months.

4. Transferring Limits

The maximum amount per transaction is one of the top requirements for creating a business checking account. Some suppliers need a minimum payment, while others have no restrictions at all. Finding a source or provider that can consistently meet your company's demands is critical.

Here at DNBC, the transaction limit can come up to 500 000 EUR/ day for business accounts.

5. Transferring Speed

Since making international business payments via bank transfer requires the person to visit the physical bank and fill out paperwork, it is considered to be extremely time-consuming. Or, when you need an instant transfer, credit unions can be the best bet. However, fees for these services are charged higher than other methods!

Online payment providers like DNBC provide lower transaction costs and the same advantages. It takes one to three business days to process most currencies, but some currencies may take longer. Here is DNBC Financial Group's average transaction speed:

- SWIFT services for international transfer: 02-05 business days
- SEPA for Eurozone transfer: 01-02 business days

Make International Payments Via Business Accounts With DNBC

DNBC Financial Group strives to become the best business account for international payments. We offer full online banking experience, money transactions in over 170 countries with multiple currencies, and are always ready to support you 24/7. Find out how DNBC can help you make international payments better.

Link:

ClickThru

Social Media:

https://www.facebook.com/dnbcfinancialgroup/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye